<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01350388</url>
  </required_header>
  <id_info>
    <org_study_id>IRB_00044016</org_study_id>
    <nct_id>NCT01350388</nct_id>
  </id_info>
  <brief_title>Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease</brief_title>
  <official_title>Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperuricemia is emerging as a risk factor for development of diabetes and metabolic
      syndrome. Recently, it was shown in in-vitro cell culture experiments that hyperuricemia
      induces redox-dependent signaling and oxidative stress in adipocytes. By targeting levels of
      uric acid with febuxostat it is hypothesized that the levels of oxidative stress in adipose
      tissue (obtained by fat biopsy) will decrease.

      Primary aims of the study are to determine whether febuxostat therapy in overweight or obese,
      diabetic patients with stage 3 Chronic Kidney Disease (CKD) and high serum uric acid levels

        1. will affect adipose tissue concentrations of thiobarbituric acid reactive substance
           (TBARS), a marker of oxidative stress

        2. will affect adipose tissue expression and concentrations of adiponectin; and

        3. will affect urinary concentrations of transforming growth factor (TGF)- B1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperuricemia is highly prevalent in the US population and commonly clusters with obesity and
      metabolic syndrome. It remains controversial whether this reflects an epiphenomenon or
      connotes a causal role of hyperuricemia in metabolic syndrome. If indeed hyperuricemia plays
      a causal role in metabolic syndrome, it would be expected that hyperuricemia will impact on
      the molecular signals that mediate the effects of adiposity on inflammation and insulin
      resistance.

      Adipokines, the protein hormones produced by the adipocytes, serve as the signals for the
      effects of adipocytes on insulin resistance, dyslipidemia, hypertension, inflammation and
      atherosclerosis. Adipokines include tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6),
      plasminogen activator inhibitor (PAI-1), leptin, angiotensinogen and adiponectin. In obesity,
      the production of TNF-α, IL-6, PAI-1, leptin and angiotensinogen increases whereas the
      production of adiponectin decreases. Increased expression of pro-inflammatory TNF-α and IL-6
      and decreased expression of anti-inflammatory adiponectin by adipocytes results in insulin
      resistance and inflammation.

      As oxidative stress in adipose tissue is considered to play a critical role in dysregulation
      of adipokines production in obesity and that hyperuricemia induces oxidative stress in
      adipocytes, it is hypothesized that hyperuricemia alters adipose tissue production of
      adipokines; therefore, febuxostat therapy will decrease hyperuricemia and thereby, have
      beneficial effects on adipokine production by adipose tissue; the favorable effects on
      adipokine production by febuxostat therapy will result in decrease in plasma levels of
      markers of inflammation; and as a result of the above, urinary markers of kidney disease will
      improve.

      Chronic Kidney Disease (CKD) patients with type 2 diabetes will be studies because this
      population has a high prevalence of hyperuricemia and likely represents a target population
      which might benefit from reduction of uric acid levels.

      This is a placebo-controlled, double-blinded, randomized controlled trial to examine the
      effects of uric acid lowering with oral febuxostat on adipokines and markers of inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Thiobarbituric Acid Reactive Substance (TBARS) Concentration in Adipose Tissue From Baseline to 24 Weeks</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>The percent difference in thiobarbituric acid reactive substance (TBARS) concentration geometric mean values from baseline to 24 weeks was calculated for each arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Adiponectin Concentration in Adipose Tissue From Baseline to 24 Weeks</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>The percent difference in adiponectin concentration geometric mean values from baseline to 24 weeks was calculated for each arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urinary Concentrations of Transforming Growth Factor-beta1 (TGF-beta1) From Baseline to 24 Weeks</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>The percent difference in TGF-beta1 concentration geometric mean values from baseline to 24 weeks was calculated for each arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Tumor Necrosis Factor-α (TNF-α) Concentration in Plasma From Baseline to 24 Weeks</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>The percent difference in plasma TNF-α concentration geometric mean values from baseline to 24 weeks was calculated for each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin-6 (IL-6) Concentration in Plasma From Baseline to 24 Weeks</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>The percent difference in plasma IL-6 concentration geometric mean values from baseline to 24 weeks was calculated for each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in High Sensitivity C-Reactive Protein (hsCRP) Concentration in Plasma From Baseline to 24 Weeks</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>The percent difference in plasma hsCRP concentration geometric mean values from baseline to 24 weeks was calculated for each arm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>80 mg/day of febuxostat for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 placebo tablet per day for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>80 mg/day of febuxostat for 24 weeks</description>
    <arm_group_label>Febuxostat</arm_group_label>
    <other_name>Uloric</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 placebo tablet per day for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  BMI &gt; 25 kg/m2

          -  type 2 diabetes

          -  serum uric acid ≥ 5.5 mg/dl in men and ≥ 4.6 mg/dl in women

          -  eGFR 30-60 mL/min/1.73m2

        Exclusion Criteria:

          -  History of gout

          -  concurrent use of azathioprine, mercaptopurine, theophylline, allopurinol,
             thiazolidinediones or warfarin

          -  concurrent use of metformin

          -  current antibiotic therapy

          -  pregnant women

          -  prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srinivasan Beddhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2011</study_first_submitted>
  <study_first_submitted_qc>May 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2011</study_first_posted>
  <results_first_submitted>June 6, 2016</results_first_submitted>
  <results_first_submitted_qc>August 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 3, 2016</results_first_posted>
  <last_update_submitted>August 9, 2016</last_update_submitted>
  <last_update_submitted_qc>August 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Srinvasan Beddhu</investigator_full_name>
    <investigator_title>Srinivasan Beddhu, MD Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Febuxostat</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Hyperuricemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Febuxostat</title>
          <description>Febuxostat: 80 mg/day of febuxostat for 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: 1 placebo tablet per day for 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Febuxostat</title>
          <description>Febuxostat: 80 mg/day of febuxostat for 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: 1 placebo tablet per day for 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="10"/>
                    <measurement group_id="B2" value="68" spread="11"/>
                    <measurement group_id="B3" value="68" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma Uric Acid Level</title>
          <units>milligram per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.2" spread="1.5"/>
                    <measurement group_id="B2" value="7.1" spread="1.2"/>
                    <measurement group_id="B3" value="7.2" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated Glomerular Filtration Rate (eGFR)</title>
          <units>milliliters per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.2" spread="15.3"/>
                    <measurement group_id="B2" value="54.8" spread="19.0"/>
                    <measurement group_id="B3" value="53.5" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Thiobarbituric Acid Reactive Substance (TBARS) Concentration in Adipose Tissue From Baseline to 24 Weeks</title>
        <description>The percent difference in thiobarbituric acid reactive substance (TBARS) concentration geometric mean values from baseline to 24 weeks was calculated for each arm</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat</title>
            <description>Febuxostat: 80 mg/day of febuxostat for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 1 placebo tablet per day for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Thiobarbituric Acid Reactive Substance (TBARS) Concentration in Adipose Tissue From Baseline to 24 Weeks</title>
          <description>The percent difference in thiobarbituric acid reactive substance (TBARS) concentration geometric mean values from baseline to 24 weeks was calculated for each arm</description>
          <units>percent difference in geometric mean</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" lower_limit="-26.3" upper_limit="143.4"/>
                    <measurement group_id="O2" value="44.6" lower_limit="-19.3" upper_limit="159.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Adiponectin Concentration in Adipose Tissue From Baseline to 24 Weeks</title>
        <description>The percent difference in adiponectin concentration geometric mean values from baseline to 24 weeks was calculated for each arm</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat</title>
            <description>Febuxostat: 80 mg/day of febuxostat for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 1 placebo tablet per day for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Adiponectin Concentration in Adipose Tissue From Baseline to 24 Weeks</title>
          <description>The percent difference in adiponectin concentration geometric mean values from baseline to 24 weeks was calculated for each arm</description>
          <units>percent difference in geometric mean</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="-23.4" upper_limit="36.7"/>
                    <measurement group_id="O2" value="-4.1" lower_limit="-27.7" upper_limit="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Urinary Concentrations of Transforming Growth Factor-beta1 (TGF-beta1) From Baseline to 24 Weeks</title>
        <description>The percent difference in TGF-beta1 concentration geometric mean values from baseline to 24 weeks was calculated for each arm</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat</title>
            <description>Febuxostat: 80 mg/day of febuxostat for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 1 placebo tablet per day for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Concentrations of Transforming Growth Factor-beta1 (TGF-beta1) From Baseline to 24 Weeks</title>
          <description>The percent difference in TGF-beta1 concentration geometric mean values from baseline to 24 weeks was calculated for each arm</description>
          <units>percent difference in geometric mean</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8" lower_limit="4.4" upper_limit="61.5"/>
                    <measurement group_id="O2" value="10.0" lower_limit="-10.8" upper_limit="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tumor Necrosis Factor-α (TNF-α) Concentration in Plasma From Baseline to 24 Weeks</title>
        <description>The percent difference in plasma TNF-α concentration geometric mean values from baseline to 24 weeks was calculated for each arm</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat</title>
            <description>Febuxostat: 80 mg/day of febuxostat for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 1 placebo tablet per day for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tumor Necrosis Factor-α (TNF-α) Concentration in Plasma From Baseline to 24 Weeks</title>
          <description>The percent difference in plasma TNF-α concentration geometric mean values from baseline to 24 weeks was calculated for each arm</description>
          <units>percent difference in geometric mean</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.9" lower_limit="-30.6" upper_limit="16.8"/>
                    <measurement group_id="O2" value="-7.4" lower_limit="-28.3" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interleukin-6 (IL-6) Concentration in Plasma From Baseline to 24 Weeks</title>
        <description>The percent difference in plasma IL-6 concentration geometric mean values from baseline to 24 weeks was calculated for each arm</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat</title>
            <description>Febuxostat: 80 mg/day of febuxostat for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 1 placebo tablet per day for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin-6 (IL-6) Concentration in Plasma From Baseline to 24 Weeks</title>
          <description>The percent difference in plasma IL-6 concentration geometric mean values from baseline to 24 weeks was calculated for each arm</description>
          <units>percent difference in geometric mean</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.0" lower_limit="-35.3" upper_limit="-10.7"/>
                    <measurement group_id="O2" value="-9.5" lower_limit="-22.7" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in High Sensitivity C-Reactive Protein (hsCRP) Concentration in Plasma From Baseline to 24 Weeks</title>
        <description>The percent difference in plasma hsCRP concentration geometric mean values from baseline to 24 weeks was calculated for each arm</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat</title>
            <description>Febuxostat: 80 mg/day of febuxostat for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 1 placebo tablet per day for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in High Sensitivity C-Reactive Protein (hsCRP) Concentration in Plasma From Baseline to 24 Weeks</title>
          <description>The percent difference in plasma hsCRP concentration geometric mean values from baseline to 24 weeks was calculated for each arm</description>
          <units>percent difference in geometric mean</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="-16.3" upper_limit="50.3"/>
                    <measurement group_id="O2" value="-7.2" lower_limit="-30.5" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 Weeks</time_frame>
      <desc>Details of adverse events experienced, particularly hospitalizations and emergency department visits obtained at each scheduled follow-up visit through week 24.</desc>
      <group_list>
        <group group_id="E1">
          <title>Febuxostat</title>
          <description>Febuxostat: 80 mg/day of febuxostat for 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: 1 placebo tablet per day for 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Aortic Valve Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like Symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Srinivasan Beddhu, M.D.</name_or_title>
      <organization>University of Utah</organization>
      <phone>801-585-3810</phone>
      <email>srinivansan.beddhu@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

